Valuation: Insulet Corporation

Capitalization 13.81B 11.77B 10.89B 10.25B 19.1B 1,285B 19.49B 128B 49.99B 617B 51.84B 50.74B 2,198B P/E ratio 2026 *
31.6x
P/E ratio 2027 * 24.9x
Enterprise value 13.78B 11.74B 10.86B 10.23B 19.05B 1,282B 19.45B 127B 49.87B 615B 51.72B 50.62B 2,193B EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.42x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day-1.25%
1 week-3.23%
Current month-6.15%
1 month-17.34%
3 months-29.30%
6 months-37.39%
Current year-30.72%
1 week 195.28
Extreme 195.28
209
1 month 195.28
Extreme 195.28
239.97
Current year 195.28
Extreme 195.28
299.8
1 year 195.28
Extreme 195.28
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 26.5
Extreme 26.5
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Change 5d. change 1-year change 3-years change Capi.($)
-1.25%-3.23%-21.69%-37.47% 13.81B
-2.36%-1.96%-19.45%-3.29% 179B
-0.80%+1.08%+5.66%+8.69% 113B
-0.51%-0.04%+14.93%+92.82% 62.73B
+1.74%+7.94%+102.96%+108.48% 61.09B
-0.80%-0.71%-22.55%-39.17% 44.27B
-0.20%+3.92% - - 37.08B
-2.53%+1.28%-4.87%-43.11% 25.28B
-0.52%+1.19%+2.51%+15.78% 21.94B
-1.47%-1.20%-18.51%+17.05% 20.12B
Average -0.87%+2.21%+4.33%+13.31% 57.81B
Weighted average by Cap. -0.90%+2.37%+4.89%+18.84%

Financials

2026 *2027 *
Net sales 3.3B 2.81B 2.6B 2.45B 4.57B 307B 4.66B 30.55B 11.95B 148B 12.4B 12.13B 526B 3.94B 3.35B 3.1B 2.92B 5.44B 366B 5.56B 36.42B 14.25B 176B 14.78B 14.46B 627B
Net income 441M 376M 348M 328M 610M 41.06B 623M 4.08B 1.6B 19.72B 1.66B 1.62B 70.25B 567M 483M 447M 421M 784M 52.71B 800M 5.24B 2.05B 25.31B 2.13B 2.08B 90.19B
Net Debt -31.86M -27.14M -25.12M -23.65M -44.05M -2.96B -44.96M -295M -115M -1.42B -120M -117M -5.07B -329M -280M -259M -244M -455M -30.58B -464M -3.04B -1.19B -14.69B -1.23B -1.21B -52.33B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
11/04/26 196.93 $ -1.25% 705,189
09/04/26 199.42 $ -2.01% 813,820
08/04/26 203.51 $ +0.52% 702,933
07/04/26 202.46 $ -0.51% 930,592
06/04/26 203.50 $ -0.40% 1,215,170
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
199.42USD
Average target price
340.26USD
Spread / Average Target
+70.63%

Quarterly revenue - Rate of surprise